应用重组大肠杆菌表达的代表HEVORF2C端约 1 /3长度基因片段的重组蛋白作为疫苗 ,进行了猕猴接种及HEV攻击实验。结果显示 ,猕猴接种疫苗后可产生高效价的抗体 ;在同株HEV攻击后 ,疫苗组 3只猕猴除 1只出现 1次粪便标本HEVRNA阳性外 ,其他未见粪便排毒和HEV血症 ,而对照组 3只猕猴均出现粪便排毒 ,并持续 9～ 1 3天 ;其中 2只外周血单个核细胞可检测到HEVRNA ,且 1只出现ALT异常。上述结果表明 ,该疫苗可有效地保护猕猴对同株HEV的攻击 ,可作为HEV的候选疫苗 The rhesus monkey inoculation and HEV challenge experiments were carried out using the recombinant protein representing about 1/3 of the length of HEVORF2C gene expressed in recombinant E. coli as a vaccine. The results showed that the rhesus monkeys can produce high titer antibodies after vaccination. After the same strain of HEV was challenged, only 1 stool specimen positive for HEV RNA was found in one of the 3 cynomolgus monkeys in the vaccine group, while no detoxification and HEV excretion were observed in the control group All 3 macaques showed detoxification, and continued for 9 to 13 days. Two of the peripheral blood mononuclear cells detected HEVRNA, and 1 showed abnormal ALT. The above results show that the vaccine can effectively protect macaque against homologous HEV challenge and can be used as a candidate vaccine for HEV